Acute Management and Evaluation of First‑Onset Migraine with Aura

Assessment and Red‑Flag Exclusion

Immediately assess any patient with a first migraine aura for secondary headache disorders before initiating treatment, as recommended by the Neurology guideline consortium. 1
Urgent neuroimaging or specialist referral is indicated when any of the following red‑flag features are present: sudden simultaneous onset of neurological symptoms, aura lasting > 60 minutes, thunderclap headache, onset after age 50, progressive headache pattern, or altered consciousness/personality change. 2

Visual disturbances occur in > 90 % of migraine‑with‑aura episodes (e.g., fortification spectra, scintillating scotomas). 1
Aura symptoms spread gradually over ≥ 5 minutes, occur in a stereotyped sequence (visual → sensory → aphasic), each lasting 5–60 minutes, and are fully reversible. 1

First‑line therapy is an NSAID started as soon as aura begins (do not wait for headache). Recommended agents and typical adult doses:
- Ibuprofen 400–800 mg,
- Naproxen sodium 500–550 mg,
- Aspirin 900–1000 mg,
- Diclofenac potassium (dose per local formulary). [3][4]5
Triptans must not be given during the aura phase because they do not abort aura nor prevent the subsequent headache. [3][2]

If NSAID alone provides insufficient relief, add a triptan at the onset of headache. [3][4][2][5]
Any triptan (e.g., sumatriptan, rizatriptan, eletriptan, zolmitriptan, naratriptan, almotriptan, frovatriptan) should be taken early while the headache is still mild for maximal efficacy. [3][2]
When oral intake is limited by nausea/vomiting, use non‑oral formulations (nasal spray or sub‑cutaneous injection). [3][2]

Simultaneous administration of a triptan + a fast‑acting NSAID (naproxen sodium, ibuprofen lysine, or diclofenac potassium) reduces the risk of headache recurrence within 48 hours. [3][2]
If all triptans fail or are contraindicated, consider:
- CGRP receptor antagonists (rimegepant, ubrogepant, zavegepant). [4][5]
- Lasmiditan (a ditan), noting that it impairs driving for ≥ 8 hours. [4][2]5

Domperidone or metoclopramide may be used to control nausea/vomiting associated with migraine attacks. [4][2]

Opioids – ineffective and increase risk of dependence and medication‑overuse headache. [4][2]5
Barbiturates/butalbital compounds – same concerns as opioids. [4][2]
Oral ergot alkaloids – poorly effective and potentially toxic. [4][2]

Explain that migraine with aura is a neurological disorder, not a vascular emergency, but emphasize vigilance for atypical features that warrant urgent evaluation. [3][1]

Preventive treatment is generally not started after a single attack; however, it should be considered when:
- Recurrent attacks cause disability on ≥ 2 days per month despite optimized acute therapy. [4][2]
- Attack duration is unusually prolonged. 4

Advise patients to keep a headache diary tracking aura frequency, headache days per month, acute medication use, and impact on quality of life. 6
Reassess efficacy and tolerability of any preventive medication after 2–3 months, allowing adequate time at therapeutic doses before declaring failure. 4

Using triptans during the aura phase (ineffective and wasteful). [3][2]
Failing to exclude secondary causes in a first‑onset aura, especially when atypical features are present. [1][2]

Gradual spread of sensory symptoms over ≥ 5 minutes is characteristic of migraine aura, distinguishing it from abrupt onset typical of vascular events. 7, 8, 9, 10
Migraine aura commonly presents with both positive sensory phenomena (e.g., tingling, “pins‑and‑needles”) and negative phenomena (numbness), rather than isolated loss of sensation. 7
Aura symptoms usually develop sequentially—visual disturbances first, followed by sensory changes, then possible speech alterations—supporting a migraine origin. 7
Each individual aura component lasts between 5 and 60 minutes and resolves completely, a temporal pattern that helps differentiate it from persistent deficits of stroke. 7, 9, 10
The sensory aura is typically accompanied by, or followed within 60 minutes by, a headache, reinforcing the migraine diagnosis. 7, 10
A history of at least two prior, stereotyped episodes with the same pattern of symptoms strongly favors migraine aura over a new vascular event. 7, 9

Sudden, simultaneous onset of unilateral facial numbness (no gradual spread) mandates immediate neuroimaging to exclude stroke or TIA. 7, 8, 10

In patients with recurrent, stereotyped facial sensory episodes, the presence of a gradual spread ≥ 5 minutes directs clinicians toward a migraine aura work‑up rather than emergent stroke protocols. 7
When paresthesias accompany numbness, the finding supports a migraine aura diagnosis; isolated numbness without positive sensory features raises suspicion for TIA. 7
Resolution of the facial sensory disturbance within the 5‑ to 60‑minute window aligns with migraine aura and reduces the likelihood of an acute cerebrovascular event. 7, 9